Archean Chemical - Volume Off-Take In New, Existing Products To Propel Growth; DRChoksey Initiates With A Buy

DRChoksey Research Report

Archean Chemical Industries Ltd. demonstrated strong resilience in FY24, maintaining a 35% margin despite revenue and profit growth moderation.

The industrial salt segment's robust performance offset declines in bromine revenue. With Rs 130-140 crore already spent on capex, benefits from the bromine derivative business are expected to materialize starting FY25E.

We project a CAGR of 34% in revenue and 44% in net profit during FY24-FY26E, driven by volume recovery and new product lines.

Valuing the stock at a P/E multiple of 17.5x on FY26E EPS, we recommend a Buy with a target price of Rs 943.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.